Paediatric Formulation: Design and Development
The development of paediatric medicines can be challenging since this is a different patient population with specific needs. A medicine designed for use in paediatric patients must consider the following aspects: patient population variability; the need for dose flexibility; route of administration;...
محفوظ في:
| التنسيق: | Online |
|---|---|
| اللغة: | الإنجليزية |
| منشور في: |
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | ONIX_20220111_9783036507408_174 |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1869518702085406720 |
|---|---|
| collection | Directory of Open Access Books |
| description | The development of paediatric medicines can be challenging since this is a different patient population with specific needs. A medicine designed for use in paediatric patients must consider the following aspects: patient population variability; the need for dose flexibility; route of administration; patient compliance; excipient tolerability. For example, the toxicity of excipients may differ in children compared to adults and children have different taste preferences. Globally, about 75% of drugs do not carry regulatory approval for use in children; worldwide, many medications prescribed for the treatment of paediatric diseases are used off-label, and less than 20% of package inserts have sufficient information for treating children. This book provides an update on both state-of-the-art methodology and operational challenges in paediatric formulation design and development. It aims at re-evaluating what is needed for more progress in the design and development of age-appropriate treatments for paediatric diseases, focusing on: formulation development; drug delivery design; efficacy, safety, and tolerability of drugs and excipients. |
| format | Online |
| id | doab-20.500.12854ir-76438 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2022 |
| publishDateRange | 2022 |
| publishDateSort | 2022 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-764382024-03-30T23:22:21Z Paediatric Formulation: Design and Development Denora, Nunzio Lopalco, Antonio dasatinib Duchenne muscular dystrophy cyclodextrin inclusion complex phase solubility studies paediatric age liquid formulation tumorspheres retinoblastoma topotecan penetration confocal microscopy poorly water soluble drug solubility enhancement grinding spray congealing neglected tropical diseases polymorph Norvir® ritonavir poorly soluble compound pediatric palatability assessment bioavailability flavor profile Interleukin-1 anakinra canakinumab innovative biotechnologies autoinflammatory disease Kawasaki disease systemic juvenile idiopathic arthritis personalized medicine child pediatrics neonates formulation product development formulation development oral parenteral topical inhaled intra nasal biopharmaceutics administration excipient NICU device medication error dosage form modified release drug delivery paediatric formulation development paediatric dosage forms chronic myeloid leukemia tyrosine kinase inhibitors pediatric age imatinib nilotinb ponatinib Orodispersible formulation pyrazinamide pediatric drug delivery tuberculosis design of experiments children edible films development design paediatric age-related palatable taste-masking acceptable thema EDItEUR::M Medicine and Nursing The development of paediatric medicines can be challenging since this is a different patient population with specific needs. A medicine designed for use in paediatric patients must consider the following aspects: patient population variability; the need for dose flexibility; route of administration; patient compliance; excipient tolerability. For example, the toxicity of excipients may differ in children compared to adults and children have different taste preferences. Globally, about 75% of drugs do not carry regulatory approval for use in children; worldwide, many medications prescribed for the treatment of paediatric diseases are used off-label, and less than 20% of package inserts have sufficient information for treating children. This book provides an update on both state-of-the-art methodology and operational challenges in paediatric formulation design and development. It aims at re-evaluating what is needed for more progress in the design and development of age-appropriate treatments for paediatric diseases, focusing on: formulation development; drug delivery design; efficacy, safety, and tolerability of drugs and excipients. 2022-01-11T13:31:57Z 2022-01-11T13:31:57Z 2021 book ONIX_20220111_9783036507408_174 9783036507408 9783036507415 https://directory.doabooks.org/handle/20.500.12854/76438 eng image/jpeg Attribution 4.0 International https://mdpi.com/books/pdfview/book/3873 https://mdpi.com/books/pdfview/book/3873 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-0741-5 10.3390/books978-3-0365-0741-5 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036507408 9783036507415 205 Basel, Switzerland open access |
| spellingShingle | dasatinib Duchenne muscular dystrophy cyclodextrin inclusion complex phase solubility studies paediatric age liquid formulation tumorspheres retinoblastoma topotecan penetration confocal microscopy poorly water soluble drug solubility enhancement grinding spray congealing neglected tropical diseases polymorph Norvir® ritonavir poorly soluble compound pediatric palatability assessment bioavailability flavor profile Interleukin-1 anakinra canakinumab innovative biotechnologies autoinflammatory disease Kawasaki disease systemic juvenile idiopathic arthritis personalized medicine child pediatrics neonates formulation product development formulation development oral parenteral topical inhaled intra nasal biopharmaceutics administration excipient NICU device medication error dosage form modified release drug delivery paediatric formulation development paediatric dosage forms chronic myeloid leukemia tyrosine kinase inhibitors pediatric age imatinib nilotinb ponatinib Orodispersible formulation pyrazinamide pediatric drug delivery tuberculosis design of experiments children edible films development design paediatric age-related palatable taste-masking acceptable thema EDItEUR::M Medicine and Nursing Paediatric Formulation: Design and Development |
| title | Paediatric Formulation: Design and Development |
| title_full | Paediatric Formulation: Design and Development |
| title_fullStr | Paediatric Formulation: Design and Development |
| title_full_unstemmed | Paediatric Formulation: Design and Development |
| title_short | Paediatric Formulation: Design and Development |
| title_sort | paediatric formulation design and development |
| topic | dasatinib Duchenne muscular dystrophy cyclodextrin inclusion complex phase solubility studies paediatric age liquid formulation tumorspheres retinoblastoma topotecan penetration confocal microscopy poorly water soluble drug solubility enhancement grinding spray congealing neglected tropical diseases polymorph Norvir® ritonavir poorly soluble compound pediatric palatability assessment bioavailability flavor profile Interleukin-1 anakinra canakinumab innovative biotechnologies autoinflammatory disease Kawasaki disease systemic juvenile idiopathic arthritis personalized medicine child pediatrics neonates formulation product development formulation development oral parenteral topical inhaled intra nasal biopharmaceutics administration excipient NICU device medication error dosage form modified release drug delivery paediatric formulation development paediatric dosage forms chronic myeloid leukemia tyrosine kinase inhibitors pediatric age imatinib nilotinb ponatinib Orodispersible formulation pyrazinamide pediatric drug delivery tuberculosis design of experiments children edible films development design paediatric age-related palatable taste-masking acceptable thema EDItEUR::M Medicine and Nursing |
| topic_facet | dasatinib Duchenne muscular dystrophy cyclodextrin inclusion complex phase solubility studies paediatric age liquid formulation tumorspheres retinoblastoma topotecan penetration confocal microscopy poorly water soluble drug solubility enhancement grinding spray congealing neglected tropical diseases polymorph Norvir® ritonavir poorly soluble compound pediatric palatability assessment bioavailability flavor profile Interleukin-1 anakinra canakinumab innovative biotechnologies autoinflammatory disease Kawasaki disease systemic juvenile idiopathic arthritis personalized medicine child pediatrics neonates formulation product development formulation development oral parenteral topical inhaled intra nasal biopharmaceutics administration excipient NICU device medication error dosage form modified release drug delivery paediatric formulation development paediatric dosage forms chronic myeloid leukemia tyrosine kinase inhibitors pediatric age imatinib nilotinb ponatinib Orodispersible formulation pyrazinamide pediatric drug delivery tuberculosis design of experiments children edible films development design paediatric age-related palatable taste-masking acceptable thema EDItEUR::M Medicine and Nursing |
| url | ONIX_20220111_9783036507408_174 |